KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Assets: 2018-2024

Historic Non-Current Assets for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $5.8 million.

  • Esperion Therapeutics' Non-Current Assets fell 45.78% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 45.78%. This contributed to the annual value of $5.8 million for FY2024, which is 23.08% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Non-Current Assets of $5.8 million as of FY2024, which was up 23.08% from $4.7 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Non-Current Assets high stood at $52.6 million for FY2021, and its period low was $1.3 million during FY2022.
  • Over the past 3 years, Esperion Therapeutics' median Non-Current Assets value was $4.7 million (recorded in 2023), while the average stood at $3.9 million.
  • Per our database at Business Quant, Esperion Therapeutics' Non-Current Assets spiked by 614.72% in 2021 and then crashed by 97.61% in 2022.
  • Esperion Therapeutics' Non-Current Assets (Yearly) stood at $7.4 million in 2020, then soared by 614.72% to $52.6 million in 2021, then slumped by 97.61% to $1.3 million in 2022, then skyrocketed by 276.67% to $4.7 million in 2023, then increased by 23.08% to $5.8 million in 2024.